ReviewJournal of inflammation research2020
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature.
Review in Journal of inflammation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Molecular cytokine-dependent mechanisms of periodontitis pathogenesis and the potential for pharmacological IL-1 modulation in disease treatment.Frontiers in dental medicine · 2026Review
- Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review.The Journal of dermatology · 2025Review
- Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study.BMC rheumatology · 2025Article
- Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review.Reumatologia · 2025Review
- The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever.Clinical rheumatology · 2024Article
- Recent Insights in Pyrin Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin-Associated Autoinflammatory Syndromes.Journal of clinical immunology · 2023Review
- Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience.Pediatric rheumatology online journal · 2023Article
- Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study.Journal of clinical medicine · 2023Article
- Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF.Pediatric rheumatology online journal · 2023Article
- A novel colchicine-myricetin heterozygous molecule: design, synthesis, and effective evaluations on the pathological models of acute lung injuryFrontiers in pharmacology · 2023Article
- Treatment of refractory Yao syndrome with canakinumab.JAAD case reports · 2022Article
- The Comparison of Pediatric Patients with Familial Mediterranean Fever Originated from Turkey and Crimea.Turkish archives of pediatrics · 2022Article
- The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.International journal of molecular sciences · 2022Review
- Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.International journal of molecular sciences · 2021Review
- Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.Cytokine · 2021Review
- The Rheumatology Drugs for COVID-19 Management: Which and When?Journal of clinical medicine · 2021Review
- Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review.Frontiers in immunology · 2021Review
- Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report.Mediterranean journal of hematology and infectious diseases · 2020Article
- [Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19].Reumatologia clinicaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.